Analyst Research
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Myriad Genetics Inc Raises FY 2013 Guidance
Myriad Genetics Inc announced that for fiscal 2013, it expects total revenue of $570-$585 million and diluted earnings per share of $1.50-$1.55. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $572 million and EPS of $1.51 for fiscal 2013.
Latest Key Developments in Advanced
- Volcano Corp Announces Preliminary Results From ADVISE II Study
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Raysearch Laboratories AB publ Appoints Ernst & Young as Auditors
- Varian Medical Systems Inc Receives FDA 510(k) Clearance Of Its Nexus DRF Digital X-Ray Imaging System
- Share this
- Link this
- Digg this
Follow Reuters